|
Jan 29
|
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
|
|
Jan 29
|
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
|
|
Jan 29
|
5 Monster Stocks to Hold for the Next 10 Years
|
|
Jan 28
|
Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market
|
|
Jan 28
|
How to Play NVO Stock After New Drug's Success in Obesity Study
|
|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
From Davids to Goliaths: the GLP-1RA gold rush
|
|
Jan 2
|
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
|
|
Jan 2
|
Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs?
|
|
Jan 2
|
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
|
|
Jan 2
|
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
|
|
Jan 2
|
Should You Buy the Dip in Novo Nordisk Stock Right Now?
|
|
Jan 2
|
Tirzepatide outpacing Wegovy in the obesity space
|
|
Jan 2
|
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them
|
|
Jan 1
|
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
|
|
Jan 1
|
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
|
|
Jan 1
|
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
|
|
Dec 31
|
Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options
|
|
Dec 31
|
GLP-1 questions emerge for 2025
|
|
Dec 31
|
Novo Nordisk A/S (NVO): A Bull Case Theory
|